GO
Loading...

Pharmaceuticals

More

  • Conatus Pharma's liver drug succeeds in mid-stage study Thursday, 26 Mar 2015 | 7:02 AM ET

    March 26- Conatus Pharmaceuticals Inc said its experimental lead drug was more effective than a placebo in a mid-stage study in patients with a form of fatty liver disease. Several drugmakers, including Gilead Sciences Inc, Intercept Pharmaceuticals Inc and France's Genfit SA, are in the race to develop treatments. Conatus estimates that about 2 million...

  • Street Talk: Ultragenyx Pharmaceutical   Wednesday, 25 Mar 2015 | 2:30 PM ET
    Street Talk: Ultragenyx Pharmaceutical

    "Power Lunch" hosts Melissa Lee and Brian Sullivan look at 5 stocks with analyst recommendations, including Harley Davidson, Tesla, and Starwood Hotels.

  • A look at some key statistics on rare diseases in the US Wednesday, 25 Mar 2015 | 11:09 AM ET

    The global pharmaceutical industry is make huge investments in treatments for rare diseases, which once drew little interest from major drugmakers. A look at some key statistics on rare diseases:. —Percentage of rare diseases with an FDA- approved treatment: 5 percent.

  • Science, patients driving rare disease drug research surge Wednesday, 25 Mar 2015 | 10:38 AM ET

    TRENTON, N.J.— The global pharmaceutical industry is pouring billions of dollars into developing treatments for rare diseases, which once drew little interest from major drugmakers but now point the way toward a new era of innovative therapies and big profits. The investments come as researchers harness recent scientific advances, including the mapping of...

  • Sun Pharmaceuticals completes buyout of Ranbaxy Wednesday, 25 Mar 2015 | 8:56 AM ET

    NEW YORK— Sun Pharmaceutical Industries Ltd. said Wednesday that it has completed its buyout of Ranbaxy Laboratories. The deal, announced in April, is worth about $4 billion and combines two of India's largest pharmaceutical companies. As of the close of the deal, Japan's Daiichi Sankyo becomes the second largest shareholder in Sun Pharma.

  • KENILWORTH, N.J.— Merck& Co. says its board approved the repurchase of up to $10 billion more of its stock. The drugmaker said Tuesday that amount will be added to the $1.7 billion remaining available for repurchase under a prior authorization. Shares of the Kenilworth, New Jersey- based company rose 86 cents, or 1.5 percent, to $59.49 in aftermarket trading...

  • Merck increases share buyback program by $10 bln Tuesday, 24 Mar 2015 | 5:24 PM ET

    March 24- Drugmaker Merck Inc said its board authorized an additional share repurchase of up to $10 billion of the company's common stock. The total outstanding share repurchase authorization is now about $11.7 billion, the company said on Tuesday. Shares of the company, which has a market capitalization of about $166 billion, were up 1.39 percent at $59.45 in...

  • FDA to evaluate homeopathy regulatory framework Tuesday, 24 Mar 2015 | 2:31 PM ET

    March 24- The U.S. Food and Drug Administration said it would hold a public hearing seeking information and comment on the use of products labeled' homeopathic', as well as the agency's regulatory framework for such products. The FDA issued a warning earlier this month asking consumers not to rely on asthma products labeled homeopathic that are sold over the...

  • March 24- Merck& Co Inc said on Tuesday that it would stop a large study of its Keytruda melanoma treatment early because an independent monitoring committee determined the drug succeeded in its goal of prolonging survival in previously untreated patients at advanced stage of the disease. The medicine, a PD-1 inhibitor that works by taking the brakes off the...

  • March 24- Bristol-Myers Squibb said on Tuesday it had agreed to acquire rights to a Novo Nordisk immune system research program, which the Danish company is divesting as it focuses further on diabetes care. The project aims to modulate the innate immune system as a therapy for autoimmune diseases and the U.S. drugmaker said it fitted with its long-standing...

  • Biogen downgrade, Pfizer rises   Monday, 23 Mar 2015 | 2:14 PM ET
    Biogen downgrade, Pfizer rises

    CNBC's Meg Tirrell reports the latest on Stifel downgrading Biogen and Pfizer making a positive move. CNBC's Brian Sullivan and Melissa Lee weigh in on the biotech sector.

  • Biogen Idec shortens its name to Biogen Monday, 23 Mar 2015 | 8:54 AM ET

    NEW YORK— Biogen Idec Inc. is shortening its name to just Biogen as of Monday. The company was created 12 years ago through the merger of Biogen with IDEC Pharmaceuticals and has since focused on three core areas, including neurology, immunology and hematology. Biogen, based in Cambridge, Massachusetts, makes blockbuster multiple sclerosis treatments Avonex...

  • *Eisai jumps 20 pct on Barclays' rating hike citing Alzheimer's drug hope. TOKYO, March 23- Japan's Nikkei share average rose to a fresh 15- year high on Monday, tracking gains in U.S. shares, while Eisai Co jumped over 20 percent after a brokerage upgraded the stock, citing the effectiveness of its drug to treat Alzheimer's disease. Eisai soared to a record high of...

  • March 20- An experimental drug from Biogen Idec Inc became the first Alzheimer's treatment to significantly slow cognitive decline and reduce what is believed to be brain-destroying plaque in patients with early and mild forms of the disease, according to a small study likely to reignite hopes of a treatment. Biogen is entering a field littered with...

  • Biogen's stock gets boost from Alzheimer's results

    CNBC's Meg Tirrell reports the biotech company got better than expected results regarding its Alzheimer's drug.

  • Biogen Idec released much anticipated results from a study of a potential Alzheimer's disease treatment on Friday, showing that it slowed cognitive decline in some patients. In December, the biotechnology company said the developing drug aducanumab reduced a type of plaque in the brain believed to play a key role in the disease and slowed clinical...

  • Biogen Alzheimer's drug: The results   Friday, 20 Mar 2015 | 5:40 AM ET
    Biogen Alzheimer's drug: The results

    CNBC's Meg Tirrell reports on Biogen's experimental drug for Alzheimer's and how the company appears to have exceeded expectations.

  • The FDA is not required to follow the recommendations of its experts, though it often does. Breo Ellipta is already approved in the U.S. for a type of chronic lung disease, but Glaxo is hoping to expand the drug's use to the much larger patient population of roughly 37 million Americans with asthma. In 2010, FDA required manufacturers of LABA-steroid combination...

  • NEW YORK, March 19- A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients. The judge denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat drug.

  • New Alzheimer's drug data   Thursday, 19 Mar 2015 | 1:02 PM ET
    New Alzheimer's drug data

    Biogen is set to release full data on Friday of its Alzheimer's drug, reports CNBC's Meg Tirrell.